Exenatide (Byetta ®) Regulation of Intestinal and Hepatic Lipoprotein Particle Production in Humans

NCT01056549 · Completed

Last updated 2026-05-28

This clinical trial tests how a single injection of the medication exenatide (Byetta®) affects fat processing in the intestines and liver of adults with high blood fat levels.

Status Completed The study has finished.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, single-blind basic-science study

Participants 15 people

Who can join Ages 18–60 · all sexes Healthy volunteers accepted.

Timeline Started 2010-01 · est. completion 2011-09

Where 1 site · Canada

What this study is testing ClinicalTrials.gov NCT01056549 ↗

Description as written by the study sponsor.

Exenatide acutely inhibits intestinal lipoprotein particle production. We are unable to speculate whether exenatide affects hepatic lipoprotein production in humans since there is currently no evidence from animal models or in vitro studies that have demonstrated an effect

Treatments tested

exenatide also known as Byetta Drug

In each study, the subjects will receive s.c. injection of either exenatide or matched placebo, in the Metabolic Testing Center and 2 hours prior to the start of the lipoprotein turnover study. Subjects will be blinded with regard to the treatments.

Main thing measured	The objective is to examine the change in apoB48 production rate after one subcutaneous injection of exenatide, under conditions of a pancreatic clamp and a steady state fed state.
Sponsor	University Health Network, Toronto
Conditions studied	Hyperlipidemia
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01056549 ↗